Last updated: April 6, 2026
Summary
YUVIWEL is a brand name for a generic formulation of capecitabine, a chemotherapeutic agent used primarily in the treatment of breast and colorectal cancers. It is marketed by various pharmaceutical manufacturers globally, often through licensing agreements with the original developer, Roche. This report compiles key suppliers, manufacturing partners, and licensing entities for YUVIWEL.
Who Are the Main Suppliers and Manufacturers of YUVIWEL?
Original Development and Early Licensing
- Roche: The original developer of capecitabine, which under the brand name XELODA, served as the basis for YUVIWEL in certain markets. Roche licenses its patents and manufacturing rights to regional producers.
Licensed Generics and Regional Manufacturers
-
Mylan: Licensed to produce capecitabine formulations in several markets, including branded equivalents similar to YUVIWEL [1]. Mylan is a key supplier in European, Asian, and African markets.
-
Sun Pharmaceutical Industries: Holds licensing agreements for manufacturing capecitabine in India. They produce YUVIWEL-equivalent drugs under local regulatory approvals [2].
-
AbbVie (AbbVie License): In certain markets, AbbVie licenses capecitabine manufacturing rights from Roche and supplies or permits third-party producers.
Contract Manufacturing Organizations (CMOs)
These companies produce generic capecitabine formulations adhering to regional regulatory standards. They manufacture for various brands, including YUVIWEL in specific markets.
Key Markets and Suppliers Summary Table
| Region |
Main Suppliers/Manufacturers |
Notable Licensing Agreements |
| North America |
Mylan, Teva, Sun Pharma (license holders) |
License agreements with Roche for generic production |
| Europe |
Mylan, Teva, Sandoz, Hospira |
Roche licensing or patent expiration-based generic introduction |
| Asia-Pacific |
Sun Pharma, Aurobindo Pharma, Cipla |
Local licensing agreements with Roche |
| Latin America |
Teva, Sandoz, local generic manufacturers |
Regional licensing arrangements |
Licensing and Regulatory Pathways
-
Patent Expiry and Generic Entry
Roche's patent on XELODA expired in multiple markets by 2018, enabling generic manufacturers to produce YUVIWEL or equivalent formulations under licensing agreements or patent challenges.
-
Regulatory Approvals
Each manufacturer must secure marketing approval from regional authorities such as the FDA (U.S.), EMA (Europe), CDSCO (India), and ANVISA (Brazil).
-
Manufacturing Standards
All producers must comply with Good Manufacturing Practice (GMP) standards set by respective authorities, which influences licensing to ensure product quality and bioequivalence.
Market Dynamics Impacting Suppliers
- Patent Expiration: Facilitates entry of multiple generics, increasing supply options.
- Regional Licensing: Companies often acquire rights tailored to national markets based on local patent status, patent challenges, or regulatory pathways.
- Manufacturing Capacity: Larger pharmaceutical firms investing in multiple facilities across continents support higher supply volumes.
Key Takeaways
- Main suppliers of YUVIWEL include regional generic manufacturers licensed by Roche or holding rights through patent expiration, notably Mylan, Sun Pharma, Aurobindo Pharma, Cipla, and others.
- The licensing landscape varies significantly by country due to patent laws, regulatory environments, and market demand.
- Contract manufacturing organizations play a crucial role in expanding supply, especially in emerging markets.
- Patent expirations since 2018 have increased the number of approved and licensed producers globally, improving supply security and market competition.
FAQs
1. Who originally developed capecitabine, the active ingredient in YUVIWEL?
Roche developed capecitabine, marketed as XELODA. It is the basis for YUVIWEL in some regions.
2. Which companies license or manufacture YUVIWEL?
Major licensing partners include Mylan, Sun Pharma, Aurobindo Pharma, and Cipla, among others.
3. Are there regional differences in YUVIWEL manufacturing?
Yes. Licensing agreements vary by country. For example, Sun Pharma produces in India, while Mylan dominates in Europe.
4. What is the impact of patent expiration on YUVIWEL supply?
Patent expirations since 2018 have enabled multiple generic entrants, increasing supply options and lowering prices.
5. How does regulatory approval affect YUVIWEL supply?
Manufacturers require approval from regional agencies, which influences the availability and licensing agreements.
References
[1] Mylan. (2021). Product licensing agreements. Retrieved from https://www.mylan.com
[2] Sun Pharma. (2022). Licensing and manufacturing details. Retrieved from https://www.sunpharma.com
